Apollo Pharmacy withdraws advisory on Ranbaxy drugs

Updated - November 16, 2021 08:45 pm IST

Published - June 13, 2013 10:55 pm IST - NEW DELHI:

An Apollo Health Care Center in Srinagar. File photo

An Apollo Health Care Center in Srinagar. File photo

A week after issuing ‘cautionary advisory’ against drugs made by Ranbaxy Laboratories, pharmacy chain Apollo Pharmacy, on Thursday, said it had resolved the matter, and would continue to sell the drug-maker’s medicines from its outlets across the country.

“We are glad that this issue has been resolved. We will continue to stock and dispense Ranbaxy products across all our pharmacies,” Apollo Pharmacy said in a statement.

Last week, it had issued a ‘cautionary advisory’ against drugs made by Ranbaxy Laboratories. Questions have been raised over drugs supplied by Ranbaxy after the company pleaded guilty to ‘felony charges’, and agreed to pay $500 million penalty in May for violation of approved drug manufacturing standards at its two plants in India.

The pharmacy chain, part of Chennai-based Apollo Hospitals, said it had been working with Ranbaxy over the past week to validate the necessary documentation in line with quality standards followed by international quality certifying authorities.

“Ranbaxy has provided us batch quality certification for all their products certified by the government approved third-party certifying laboratories.

The reports completely satisfy the quality norms stipulated by the Department of Pharmaceuticals, Government of India as well as the Drug and Cosmetic Act 1940,” the spokesperson said.

Apollo Pharmacy said it had also understood the stance of the DGHS of India in this regard and received confirmation from them that there were no quality issues in Ranbaxy Products now marketed in India.

Apollo Pharmacy has over 1,500 stores across the country.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.